21-051 Cell & Gene Therapy Technologies and Supplies

Cell and gene therapy (CGT) is a rapidly evolving field producing powerful new treatments for cancers and genetic diseases, and expanding into autoimmune disease, cardiovascular disease, musculoskeletal disease, and many others. The CGT field has generated great interest and hope among researchers, patient groups, and regulators, which has led to huge investments in R&D. Globally, many governments and regulatory bodies have adopted policy and patent environments supportive of CGT development. Since CGTs often target rare and underserved disease areas for which few other therapeutics exist, there is a sense of urgency within the pharma/bio space to develop CGTs.

As development and market entries of CGTs accelerate, the market for suppliers of laboratory and clinical tools within the CGT R&D and manufacturing spaces will see very rapid growth. The 2021 Cell & Gene Therapy Techniques and Supplies Report examines the global market for analytical technologies and products used throughout the various stages of CGT development and manufacturing, evaluating 21 technologies grouped into six categories. The goal of this report is to provide demand growth projections by technique, region, and function, while also providing comprehensive views of the competitive landscape for each technology.

Report Overview
• CGT market background and current opportunities and challenges
• Market demand and five-year forecasts, segmented by technique, region, and function
• Analysis of 21 techniques within the following six categories:
o General Techniques
o Gene Therapy Development
o Transduction and Transfection
o Cell Enrichment
o Cell Expansion
o Cryopreservation

• Competitive landscape and market shares of vendors in each technique. Participants include the following:
o Agilent
o BC Biosciences
o Bio-Rad
o Corning
o Cytiva (Danaher)
o Gibco (Thermo Fisher)
o Lonza
o MilliporeSigmat
o Miltenyi Biotec
o Roche
o Sartorius
o STEMCELL Technologies
o Thermo Fisher